Drug intelligence / Profile preview

birociclib

Development stage: Phase 2
Lead developer: Xuanzhu Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Birociclib is a selective, orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are essential for cell cycle progression from the G1 to S phase by phosphorylating the retinoblastoma protein (pRb), which leads to cellular proliferation. By inhibiting CDK4/6, birociclib blocks this pathway, thereby slowing or stopping the growth of cancer cells. The drug is designed as a targeted therapy for cancers where this pathway is dysregulated[8]. Birociclib's mechanism of action is similar to other CDK4/6 inhibitors such as ribociclib, palbociclib, and abemaciclib.

Targets

CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on birociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on birociclib.

Explore the full profile